Collaboration - September 29, 2026
AstraZeneca takes USD 2 billion stake in Summit
The company is investing USD 2 billion in Summit Therapeutics and launching a clinical collaboration that will combine Summit's PD-1/VEGF bispecific antibody ivonescimab with AstraZeneca's antibody drug conjugates (ADCs), starting in gastrointestinal cancers.
Agreement - September 29, 2026
Novo licenses oral obesity candidate from Hengrui
The company has signed an exclusive license agreement with China's Hengrui Pharma for HRS-1596, a once-weekly oral GLP-1/GIP dual receptor agonist, in a deal worth up to USD 2.6 billion.
Clinical Trials - September 29, 2026
Cinclus Pharma completes patient visits in Phase III study
All planned patient visits have now been completed in the company's Phase III HEEALING1 study of linaprazan glurate in erosive GERD. Topline results are still expected in Q4 2026.
Clinical Trials - September 29, 2026
Retogatein delays insulin dependence in genetic subgroup
Long-term follow-up of the DiAPREV-IT trial shows that two subcutaneous injections of retogatein (GAD-alum) delayed progression to insulin-dependent, stage 3 type 1 diabetes by more than five years in a genetically defined subgroup of children.
Biotech article - September 29, 2026
Beyond manufacturing: Stockholm turns to multiomics to improve cell and gene therapies
Stockholm-Uppsala has built substantial clinical, research, and manufacturing capabilities around advanced therapies. Bringing those strengths closer to the region's expertise in proteomics, genomics, and other molecular technologies could help answer the next questions in cell and gene therapy: why treatments work, why they fail, and how more patients can benefit.
MedTech Business - September 28, 2026
Arjo targets SEK 350 million EBIT improvement under new strategy
Arjo has presented a new strategy at its Capital Markets Day, committing to improve EBIT by approximately SEK 350 million (±25 million) compared with 2025, by mid-2029.
